Bone Marrow Transplant in Children: Relapsed Leukemia and Sickle Cell Disease

Dr. Danewa recommended Nathan and Oski's Hematology and Oncology of Infancy and Childhood as the primary reference, alongside Lanzkowsky's Manual of Pediatric Hematology and Oncology, and offered to share his own treatment protocols and presentations directly with any doctor who requests them.

For relapsed ALL, inotuzumab and blinatumomab are both available. Inotuzumab is the more affordable option since it only requires day-care admission, roughly 10,000 to 12,000 US dollars per cycle (day 1, 8 and 15), and some manufacturers offer buy-one-get-one support schemes. Blinatumomab is costlier, at 30 to 40 lakh Indian rupees, because it requires 28 days of hospitalization with continuous infusion, so it is used far less often for international patients. Anti-GD2 therapy (dinutuximab) for neuroblastoma runs around 70 to 80 lakh rupees, though the price has been coming down.

Dr. Danewa put inotuzumab at roughly 10,000 to 12,000 US dollars per cycle, noted that the 70 to 80 lakh rupee cost of dinutuximab converts to about 80,000 US dollars, and priced brentuximab plus nivolumab immunotherapy for Hodgkin lymphoma in a similar range to inotuzumab, around 12,000 to 15,000 US dollars.

Dr. Danewa explained that upfront bone marrow transplant has no role in most pediatric leukemia. It is reserved for cases without morphological remission (blasts above 10% at the end of induction), for hypodiploidy (fewer than 44 chromosomes), or for relapse. For benign conditions, the leading indication, especially in Africa, is sickle cell disease, where earlier transplant, ideally before age 12 and before pain crises, stroke or chest syndrome accumulate, gives a better outcome. He described three transplant types: matched sibling, matched unrelated donor via registry, and haploidentical transplant from a parent, with haploidentical success running around 70 to 80% depending on the underlying disease.

Yes. Dr. Danewa confirmed bone marrow transplant is a cure for sickle cell disease, and that outcomes are best the earlier it is done, since delay allows organ damage and comorbidities to accumulate and lowers the chance of success.

It is not used as a first-line treatment. It is reserved for specific situations: failure to reach morphological remission, defined as more than 10% blasts remaining at the end of induction chemotherapy, a hypodiploid subtype with fewer than 44 chromosomes, or relapse after the initial course of treatment.

The indications named are two or more pain crises in a year, any stroke, or acute chest syndrome.

Not yet. Gene therapy is emerging as a future option, but is not yet a practical alternative to transplant.

A matched sibling donor gives the best outcome. A matched unrelated donor, located through a donor registry, gives a somewhat lower success rate. A haploidentical, or half-match, transplant, typically from a parent, now succeeds in roughly 70 to 80% of cases, depending on the underlying disease being treated.